StockNews.com Initiates Coverage on Minerva Neurosciences (NASDAQ:NERV)

Equities research analysts at StockNews.com began coverage on shares of Minerva Neurosciences (NASDAQ:NERV) in a research report issued on Friday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright restated a “neutral” rating and issued a $5.00 price objective on shares of Minerva Neurosciences in a research note on Wednesday, November 6th.

Minerva Neurosciences Trading Up 0.9 %

Shares of NASDAQ NERV opened at $2.16 on Friday. The stock has a market cap of $15.10 million, a P/E ratio of -4.91 and a beta of 0.11. The stock has a 50 day moving average of $2.32 and a two-hundred day moving average of $2.74. Minerva Neurosciences has a twelve month low of $2.06 and a twelve month high of $13.49.

About Minerva Neurosciences

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.